Find in Library

A single-center study was conducted on 120 patients with inherited disorders of primary hemostasis followed at our hematological center. These patients presented a variety of bleeding symptoms; however, they had no definitive diagnosis. Establishing a diagnosis has consequences for the investigation of probands in families and for treatment management; therefore, we aimed to improve the diagnosis rate in these patients by implementing advanced diagnostic methods. According to the accepted international guidelines at the time of study, we investigated platelet morphology, platelet function assay, light-transmission aggregometry, and flow cytometry. Using only these methods, we were unable to make a definitive diagnosis for most of our patients. However, next-generation sequencing (NGS), which was applied in 31 patients, allowed us to establish definitive diagnoses in six cases (variants in <i>ANKRD26</i>, <i>ITGA2B</i>, and <i>F8</i>) and helped us to identify suspected variants (<i>NBEAL2</i>, <i>F2</i>, <i>BLOC1S6</i>, <i>AP3D1</i>, <i>GP1BB</i>, <i>ANO6</i>, <i>CD36</i>, and <i>ITGB3)</i> and new suspected variants (<i>GFI1B</i>, <i>FGA</i>, <i>GP1BA</i>, and <i>ITGA2B</i>) in 11 patients. The role of NGS in patients with suspicious bleeding symptoms is growing and it changes the diagnostic algorithm. The greatest disadvantage of NGS, aside from the cost, is the occurrence of gene variants of uncertain significance.